FILE PHOTO: Vials labeled “VACCINE Coronavirus COVID-19” and a syringe are seen in front of a displayed Novavax logo in this illustration taken December 11, 2021. REUTERS/Dado Ruvic/Illustration
SEOUL — South Korea has authorized the use of Novavax Inc’s COVID-19 vaccine, the food and drug safety ministry said on Wednesday.
South Korean vaccine developer SK Bioscience Co Ltd said it will produce the Novavax vaccine.
The two-dose, protein-based vaccine has secured authorizations from European Union regulators and the World Health Organization.
It has been authorized in India, Indonesia and the Philippines, where Novavax’s partner, Serum Institute of India, will supply it.
Novavax is awaiting approval in Japan, where its vaccine would be manufactured and distributed by Takeda Pharmaceutical.
South Korea has already authorized vaccines made by AstraZeneca Inc, Moderna Inc, Pfizer and Johnson & Johnson’s Janssen.